This protocol sets out measures for the follow-up and management of individuals exposed to infected animals and human cases of avian influenza, and for the public health management of possible and confirmed human cases.
Joint statement by the European Centre for Disease Prevention and Control, European Chemicals Agency, European Environment Agency, European Food Safety Authority and European Medicines Agency.
This document describes how to strengthen surveillance in hospital settings for the identification of severely affected patients infected with avian influenza virus in the EU/EEA.
Since the risk assessment published by ECDC in August 2021 on the risk of vCJD disease transmission via blood and PDMP manufactured from donations obtained in the UK, no new cases of vCJD associated with dietary exposure or transfusion of blood or blood components have been reported in EU/EEA or in the rest of the world.
This document aims to provide guidance for public health and laboratory experts in identifying human infections with animal influenza viruses as early as possible to provide early warning and inform risk assessments and public health measures.
The Protocol is targeted at the national public health reference laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.
This document provides laboratories with a single protocol for producing recombinant full-length hamster prion protein and using it to perform the Real-Time Quaking-Induced Conversion assay (RT-QuIC), which can distinguish sporadic Creutzfeldt-Jakob disease (sCJD) from variant Creutzfeldt-Jakob disease (vCJD).
This operational guidance, developed by ECDC in collaboration with its hepatitis E virus (HEV) expert group, offers options on the implementation or adjustment of HEV surveillance at a national level.
This document explains the operating procedures of the European Legionnaires’ Disease Surveillance Network, coordinated by ECDC. It specifically relates to reporting cases of travel-associated Legionnaires’ disease arising from stays in hotel or other commercial holiday accommodation. The aim is to quickly identify and control outbreaks of the disease and minimise the risk to holidaymakers. This edition supersedes the January 2012 edition.
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.